SAN FRANCISCO – Calling "unconscionable" the way some Alzheimer's disease (AD) trials have gone about enrollment and pointing to the misguided approach as a reason many experiments failed, University of Oxford neuroscience professor Simon Lovestone told a packed room at the BIO International Convention that studies have tested patients when "it's already too late."